Jordi Rodon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jordi Rodon has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Kyriakos Papadopoulos
South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
1 shared publicationMaria D Iniesta
University of Michigan, Department of Internal Medicine and Comprehensive Cancer Center, Ann Arbor, MI, USA
1 shared publicationRazelle Kurzrock
Investigational Cancer Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
1 shared publication- Robert Jean Ferry
Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA
1 shared publication Victoria DeSantos
Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication
Latest Publications
- 21 November 2008
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (1) , 31-43
Development of PARP inhibitors in oncology
(2009). Development of PARP inhibitors in oncology. Expert Opinion on Investigational Drugs: Vol. 18, No. 1, pp. 31-43. doi: 10.1517/13543780802525324
- 21 November 2008
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (1) , 31-43
Development of PARP inhibitors in oncology
(2009). Development of PARP inhibitors in oncology. Expert Opinion on Investigational Drugs: Vol. 18, No. 1, pp. 31-43. doi: 10.1517/13543780802525324
- 1 September 2008
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (9) , 2575-2588
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone–IGF–IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment. [Mol Cancer Ther 2008;7(9):2575–88]
- 1 September 2008
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (9) , 2575-2588
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone–IGF–IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment. [Mol Cancer Ther 2008;7(9):2575–88]